All News

New research highlights the significant health risks of respiratory syncytial virus (RSV) in older adults, emphasizing the need for effective vaccines and public health strategies.

In the first half of 2025, the FDA approved 7 novel drugs for oncologic conditions, including for non-small cell lung cancer; ovarian cancer; and metastatic, hormone receptor-positive, human epidermal growth factor 2-negative breast cancer.

When infected with SARS-CoV-2, the virus that causes COVID-19, higher levels of proinflammatory cytokines are released in men compared with women, leading to more severe disease.

Lenacapavir becomes the first and only twice-yearly option for HIV prevention.

Combining omega-3 supplements with exercise enhances immune response and alleviates tooth infections, offering new insights into managing apical periodontitis.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Accurate utility estimates are critical to providing a comprehensive view of quality of life for children impacted by pneumococcal disease.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

New research reveals a significant link between type 2 diabetes, obesity, and fatty liver disease.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

The FDA approves garadacimab-gxii, a treatment for hereditary angioedema (HAE), offering convenient monthly self-injections for patients 12 years and older.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

From protecting the 340B Drug Pricing Program to expanding payment pathways through state-level reforms and Medicare Advantage opportunities, Kraus emphasized the critical role pharmacists play in evolving care models.

The authors note that the combinatorial principal component analysis (cPCA) may be effective in other complex diseases outside of chronic kidney disease (CKD).

Clostridioides difficile (C difficile) represents a serious public health threat, with pharmacists and advocacy organizations playing critical roles in prevention, education, and management.

This single-center, descriptive, retrospective chart review identified barriers to outpatient chemotherapy use, revealing avoidable inpatient stays and highlighting targets for stewardship interventions.

The opportunity to optimize all medications, not just those that require a prescription, is long overdue.

Eli Lilly is expanding access to tirzepatide, a groundbreaking GLP-1 medication for weight management, offering more affordable options for obesity treatment.

Discover the latest FDA-approved treatments, including Dupixent for chronic urticaria and Valtoco for seizure clusters, enhancing patient care options.

Host Craig Beavers chats with Shannon Finks, PharmD, FCCP, BCPS, BCCP, AHSCP-CHC, president and director of pharmacy services at ZupMed in Memphis, Tennessee.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Nemolizumab shows promising long-term efficacy in reducing itch and skin lesions for atopic dermatitis, enhancing quality of life for patients.

Bispecific therapies require clearer terminology to improve safety and communication.

The subcutaneous infusion is indicated for pediatric patients aged 6 to 17 years who weigh less than 60 kg.